| 朱杰,储岳峰,张斌,等.不同射血分数心力衰竭的药物治疗进展[J].安徽医药,2026,30(3):430-435. |
| 不同射血分数心力衰竭的药物治疗进展 |
| Advances in pharmacotherapy for heart failure with different ejection fractions |
| |
| DOI：10.3969/j.issn.1009-6469.2026.03.002 |
| 中文关键词: 心力衰竭 射血分数 神经分泌系统 沙库巴曲 缬沙坦 美托洛尔 索格列净 维立西呱 螺内酯 伊伐布雷定 洋地黄 指南指导的药物治疗 预后 |
| 英文关键词: Heart failure Ejection fraction Neurosecretory systems Sacubitril Valsartan Metoprolol Soragliflozin Vericiguat Spironolactone Ivabradine Digitalis Guideline-directed medical therapy Prognosis |
| 基金项目:国家自然科学基金资助项目( 82000261)；安徽医科大学校科研基金项目( 2020xkj228，2021xkj099)；六安市人民医院科研课题项目( 2021kykt22)；六安市人民医院新技术新项目( 2025xjs71) |
|
| 摘要点击次数: 433 |
| 全文下载次数: 533 |
| 中文摘要: |
| 心力衰竭是临床常见心血管疾病之一，在我国的发病率随着人口老龄化趋势的增加而呈现同步上升的趋势，具有较高的致残率和致死率。现阶段，随着临床上对心力衰竭机制研究的深入，心力衰竭的药物治疗也在不断进展，尤其是神经内分泌调控药物的进展突出了药物治疗的重要性，以期进一步改善心力衰竭病人的住院率和病死率，同时指南指导的药物治疗的优化能控制心力衰竭的复发和进展。该研究将综合国内外多项权威临床研究的成果，首次按照不同射血分数分类，对心力衰竭病人的药物治疗进展进行综述。 |
| 英文摘要: |
| Heart failure is a common cardiovascular disease. Its incidence in China in China has been rising in parallel with the in.creasing trend of population aging, and it is associated with high rates of disability and mortality. Currently, with advances in clinical re.search on the mechanism of heart failure, drug therapy for heart failure has also been evolving. In particular, progress in neuroendo.crine-modulating agents underscores the importance of pharmacotherapy, aiming to further reduce hospitalization rate and mortalityrate in patients with heart failure. Moreover, optimization of guideline-directed medical therapy can help control the recurrence and pro.gression of heart failure. This review synthesizes findings from multiple authoritative clinical studies both in China and internationallyand, for the first time, summarizes advances in pharmacotherapy for patients with heart failure according to different ejection fractions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
